Share Name Share Symbol Market Type Share ISIN Share Description
Tristel Plc LSE:TSTL London Ordinary Share GB00B07RVT99 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +11.50p +4.36% 275.00p 270.00p 280.00p 275.00p 263.50p 263.50p 106,454 12:23:17
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 20.3 4.0 8.1 34.1 117.85

Tristel (TSTL) Latest News

More Tristel News
Tristel Takeover Rumours

Tristel (TSTL) Share Charts

1 Year Tristel Chart

1 Year Tristel Chart

1 Month Tristel Chart

1 Month Tristel Chart

Intraday Tristel Chart

Intraday Tristel Chart

Tristel (TSTL) Discussions and Chat

Tristel Forums and Chat

Date Time Title Posts
16/11/201719:40The TRISTEL story2,424
15/7/201512:01Tristel PLC: Cleaning up the sector340
03/1/201004:54tristel with charts-
14/3/200612:13MRSA cleaner246
13/2/200607:10TSTL with Charts & News3

Add a New Thread

Tristel (TSTL) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Tristel trades in real-time

Tristel (TSTL) Top Chat Posts

Tristel Daily Update: Tristel Plc is listed in the Health Care Equipment & Services sector of the London Stock Exchange with ticker TSTL. The last closing price for Tristel was 263.50p.
Tristel Plc has a 4 week average price of 262.50p and a 12 week average price of 238.50p.
The 1 year high share price is 322.50p while the 1 year low share price is currently 143p.
There are currently 42,854,133 shares in issue and the average daily traded volume is 60,629 shares. The market capitalisation of Tristel Plc is £117,848,865.75.
james188: I very much doubt that the fall in the share price today was down to the article by Richard Beddard referenced above. In essence, it was a well written article which simply questioned whether too much future profit growth was being assumed in the share price as at the end of last week. It is less than 3 weeks ago that I bought a slug of these shares at 268p - and that was by a large distance the most I have ever paid for this share. I expect that the price will continue to bounce around. As I am still adding, I fervently hope so.
briangeeee: murray80, I understand and agree that any sale would require shareholder approval. However, after the last debacle, the board should be going the extra mile. If they're confident that there won't be a sale at a lower valuation than the performance targets, then let's make the performance conditions apply equally in both situations. Why not? You comment about it being normal for options to vest on takeover. Well perhaps, but the point is that normal options are not NIL COST. That makes all the difference. With "normal" options, directors are rewarded for an uplift in share price. With NIL COST, they may well be rewarded for a reduction in share price. Surely it's very simply to change the scheme, and more importantly, the right thing to do.
piedro: New Share Option Scheme The 2018 Scheme The 2018 Scheme will be put forward for approval by shareholders at the Company's Annual General Meeting. If the 2018 Scheme is approved 990,000 share options will be granted on 1 January 2018 as follows: · Paul Swinney 500,000 options; · Elizabeth Dixon 400,000 options; · Paul Barnes 45,000 options; · David Orr 45,000 options. The options will be exercisable at 1 penny per share and will vest in three equal tranches as follows: · One-third will vest upon the achievement of a share price of £3.50; · One-third will vest upon the achievement of a share price of £4.25; · One-third will vest upon the achievement of a share price of £5.00. To vest, the average share price of Tristel plc must be above the hurdle rate for a minimum three-month period In the event of a change of control of the Company all options will vest. Any vested but unexercised options will expire on 30 June 2021. As an additional condition, the options will only be exercisable if the holder commits to hold the resulting ordinary shares until 30 June 2021 or, if sooner, until a change of control of the Company occurs. - I would prefer @ £4.50, £6.00 and £7.50 - and do not enjoy the talk of change of control - a change of CEO and Chairman, yes AIMHO
zimbtrader: I suppose someone also has to say it... the rising share price is, quite simply, speculation on the basis that approval will be secured unconditionally. Whilst I think it is unlikely, there remains some risk of an unexpected set-back which would only result in a negative impact on the share price. I guess we each must assess where we stand and I will freely admit I have reduced my holding recently and banked a very decent capital gain to boot. I have to admit, whilst I have learnt to be happy at having banked gains, I do still look at the continual rises with a twinge of regret that I reduced my overall holding by 40%. I am only human, after all! ;-)
zimbtrader: Thank you James and Melton; both very useful for those of us that were not able to attend. The share price has reacted positively to the update and, I guess, the event. I find myself considering some further top-slicing (I topped up -a lot - below 200p). I've seen this share bubble up nicely off the back of good news only to come off the boil after a month or so which would then be an opportunity to buy back.... A profit is, after all, only a profit when it has been banked!
source: Reminder from recent IC article:- "...But we continue to like Tristel, particularly given its strong intellectual property, market leading position and opportunity to expand into the US - the world’s biggest healthcare market. Buy" Seems like drops in share price are overreaction IMO. Especially as its European and Australian Markets are far more tangible opportunities in the short term and even before considering USA potential...IMHO. Regards, Source.
rcturner2: I thought that the share price might weaken after the excitement of the results has died away, but still looking pretty robust here. The USA is the big one, if they get that right, then we will all be minted.
rcturner2: A PE of 20 is not expensive for a company that is growing this fast. The US entry is a bonus that is not priced into the share price, in my opinion.
source: Another update from Paul Scott (turning more positive)... Regards, Source. +++++++++++++ Tristel (LON:TSTL) Share price: 108.75p (up 4.6% today) No. shares: 42.2m Market cap: £45.9m (at the time of writing, I hold a long position in this share) Director purchases - I'm really not a fan of orchestrated Director share purchases after bad news, but as mentioned recently for another company, it does seem to work in some situations anyway, in helping to reassure investors. Perhaps it works in marginal situations, where confidence is beginning to return anyway, which is how I see Tristel? I reported here on 24 Feb 2016 on Tristel's interim results, and the various factors which triggered a sharp correction in the share price. My view, when the shares were at 125p at the time of writing that report, was that the price looked "a bit too high", but that the "longer term upside still looks good". The share price subsequently dropped considerably more, and went as low as the low-mid 90p's yesterday morning. At around that level, I think it was a reasonably good purchase, so I picked up a few, more of a dabble than a conviction buy. Management webinar - I was also really impressed with the webinar that TSTL management did with Equity Development yesterday lunchtime. I watched/listened, and felt that management were open in addressing the criticisms of the slowing sales growth, and the share options charge. There's no doubt they have dropped a big clanger with a badly designed share options scheme, but I think they recognise that, and were emphatic that there would be no repetition in the next 3-5 years. Various other factors mitigate my concerns over the slowing growth rate (now 8%), such as 4% being due to currency effects, and also that low margin products have been dropped - hitting turnover, but having little to no impact on profit. Overall, I take my hat off to TSTL management for being so open with private investors, and not only holding a webinar, but also a meeting in London, open to private investors. Feedback from this has also been positive. This is outstanding stuff - if only all companies were so willing to engage with their PI shareholder base - especially when contentious issues arise. TSTL is already being rewarded with a rebound in the share price. I think the glass is slowly turning from half empty, to half full again. The upside from potential US FDA approvals is something that I'd like to stick around for, as that could be a significant catalyst for future growth. I'm not sure there is necessarily much short term upside from here, but who knows? I would have thought it might recover to say 120-130p after a while.
tmfmayn: Effortless -- "There may be a reversal of part of this cost if the share price stays below 134p - anyone know?" I am not an expert on option accounting, but I would guess that a reversal of this charge would depend on a specific provision in the option documentation that could negate the options' original vesting condition. I very much doubt there is such a provision, but we can live in hope. A reversal could also occur (I think) if the directors were to forfeit their options for some reason. The charge assumes the directors will still be around to collect these options. Any reversal would be accounted for in the relevant future period as a credit to the income statement, and the amount charged in these latest results would not be restated. It seems to me that your £848k sum is in the right ball park (perhaps there are other senior managers with the same options, to get the charge to £1m) and that TSTL has decided to charge the majority of these '30-day/134p' options during this H1 period. The original announcement cited these options would vest in October this year, and become available over three years. Perhaps management expected the charge to be expensed over a few years, not just 6 months. I should add that nobody here was complaining when the shares topped 134p for 30 days during December/January -- and yet that option grant had been known since August. I guess if a company grants options dependent on share-price performance, we have to accept there will be a P&L cost when the share price goes up! It will be interesting to see when senior management receive its next batch of options, and what the associated vesting conditions are.
Tristel share price data is direct from the London Stock Exchange
Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:40 V: D:20171119 20:01:42